Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Design Therapeutics, Inc.DSGN · Entity 4991 | Chief Medical Officer | January 02, 2026 | January 05, 2026 |
| FATE THERAPEUTICS INCFATE · Entity 5968 | Chief Medical Officer | January 16, 2018 | January 17, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Design Therapeutics, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.10 · Expires 2036-01-01 | Direct | 250,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 250,000 · Balance 250,000 F1: The shares subject to the option will vest as follows: 20% of the shares will vest on January 1, 2027, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest as follows: 20% of the shares will vest on January 1, 2027, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months.
FATE THERAPEUTICS INC
Report date January 16, 2018 · Filed January 17, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.55 · Expires 2028-01-15 | Direct | 186,000 |
Reported balance
After 2018-01-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-16 · Grant · Acquired 186,000 · Balance 186,000 F2: Not applicable. F1: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 16, 2018 such that this option is fully exercisable on January 16, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 16, 2018 such that this option is fully exercisable on January 16, 2022.
F2: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 5, 2026 21:14 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock option (right to buy) · Derivative | 250,000 | $0.00 Strike: $9.10 | $0.00 |
DisclosureSEC source: 0001674703-26-000002 · form4-01052026_090112.xml · derivative · entry 1 Storgard Chris · CIK 0001674703 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares subject to the option will vest as follows: 20% of the shares will vest on January 1, 2027, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months. Read SEC document |
| May 01, 2025 Filed May 23, 2025 20:26 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001415889-25-014477 · form4-05232025_080531.xml · derivative · entry 1 Storgard Chris · CIK 0001674703 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2035-04-30 F1 · derivative.exercise_date: The shares subject to the option will vest as follows: 25% of the shares will vest on April 16, 2026 and the balance of the shares will vest in equal monthly installments thereafter over the following 36 months. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 16:06 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 186,000 | Not disclosed Strike: $6.55 | Not disclosed |
DisclosureSEC source: 0001209191-18-003921 · doc4.xml · derivative · entry 1 Storgard Chris · CIK 0001674703 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,000 Underlying: Common Stock · 186,000 shares Expires 2028-01-15 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 16, 2018 such that this option is fully exercisable on January 16, 2022. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 16:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 150,000 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0001209191-17-002631 · doc4.xml · derivative · entry 1 Storgard Chris · CIK 0001674703 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-01-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 4, 2017 such that this option is fully exercisable on January 4, 2021. Read SEC document |
| November 23, 2016 Filed Nov 28, 2016 15:46 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | PurchaseCommon Stock | 37,593 | $2.66 | $99,997.38 |
DisclosureSEC source: 0001209191-16-152160 · doc4.xml · nonDerivative · entry 1 Storgard Chris · CIK 0001674703 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Storgard Family Trust, June 28, 2012 Disclosed balance after: 37,593 F1 · shares: Represents shares acquired in a private placement pursuant to the Securities Purchase Agreement dated November 21, 2016 by and among the issuer and the purchasers named therein. F2 · ownership.nature: These shares are owned of record by The Storgard Family Trust, June 28, 2012 for which Chris M. Storgard and Melinda Storgard are co-trustees. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.